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Abstract As recognition and treatment of breakthrough
cancer pain (BcP) depend on the education and knowledge
of palliative care physicians, it is important to systemati-
cally explore the attitudes of palliative care physicians in
hospices or palliative care units. The aim of this study was
to assess the knowledge and attitudes of hospice physicians
in Italy regarding BcP and its treatment. All hospices
existing in Italy were interviewed to gather information
about provision of BP medication, drugs of choice,
preferred route of administration, methods to choose the
dose, and choice of BcP medication based on opioid
administered for background analgesia. Of 158 hospices
registered, 122 centers agreed with the interview (77.2%).
Morphine was more frequently used, either orally or
parenterally. In some hospices, oral transmucosal fentanyl
(OTFC) was unavailable. Most physicians provided doses
of opioids proportional to the opioid basal regimen,
independently of the preferred opioid or the route of
administration. The choice of dose titration was equally
used in patients who were prescribed OTFC or parenteral
morphine. The choice of breakthrough medication on the
basis of opioid basal regimen was equally distributed.
These findings suggest the need for improved education on
behalf of physicians on the assessment and treatment of
BcP, particularly in a potentially specialized setting, such as
palliative care units. The choice of BcP medications should
be based on the best cost-efficacy ratio rather than solely on
economical considerations.
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Breakthrough cancer pain (BcP) is a transient exacerbation
of pain that occurs either spontaneously or in relation to a
trigger despite adequately controlled background pain [1].
This phenomenon is common among cancer patients, with
an incidence of 40-80% [2, 3]. BcP is mainly managed with
opioids. Traditionally, normal release opioids, known as
rescue medication, are given in addition to scheduled
around-the-clock analgesics. However, immediate release
opioids, namely oral morphine, may take up to an hour to
produce analgesia. Recently, new formulations have been
developed in an effort to provide a more rapid onset of
effect. Oral transmucosal fentanyl (OTFC) has been shown
to be more effective than oral morphine and well tolerated
[4].
Despite being a prevalent phenomenon in patients with
cancer pain, BcP is often unrecognized and undertreated,
particularly in Italy, even in a palliative care setting. In a
cross-sectional multicenter study involving eight Italian
oncology and palliative care centers, BcP was treated in
59.2% of cases with extra doses of opioids, in 19.5% with
nonsteroidal anti-inflammatory drugs (NSAIDs), while
21.3% of patients had no specific treatment for BcP [5].
Thus, it seems that the crucial point for an appropriate
recognition and treatment of BcP depends on the education
and knowledge of palliative care physicians about BcP
medication to provide the correct information and prescrip-
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tion to cancer patients and their careers. Italy represents a
unique country for its specificity in cultural issues,
attitudes, organization, and a low opioid consumption [6].
In the last decade in Italy, there have been investments in
the field of community care and health districts under the
input of new legislations, and new resources from the
Health Care System have been allocated for palliative care
[7]. The aim of this study was to assess the knowledge and
attitudes of hospice physicians regarding BcP and its
treatment.
Methods
The Italian registry of palliative care institutions, named
Osservatorio Federazione cure palliative [1] was consulted
at the official website, linked to Società Italiana di Cure
Palliative to select all the palliative care units and hospices
existing in Italy until September 2009. Phone interviews
were planned with physicians who were delegated to
provide the answers. In case of failure due to the
physician’s busy schedule or wrong phone number, two
further attempts were made, eventually looking for infor-
mation from other sources.
The following information was gathered:
– Number of unit’s beds
– Provision of BcP medication
– Drugs of choice
– Preferred route of administration
– Methods to choose the dose (standard dose, propor-
tional dose, and dose titration)
– Choice of BcP medication based on opioid adminis-
tered for background analgesia
– Comments
Statistical analysis
Data were collected and analyzed by the SPSS Software
14.0 version (SPSS, Inc., Chicago, IL, USA). All contin-
uous data are expressed as a mean ± standard deviation of
the mean. Statistical analysis of quantitative data, included
descriptive statistics, was performed for all the items.
Frequency analysis was performed with chi-square test.
Results
A large amount of hospices was recorded in North Italy in
comparison with Southern Italy, including islands (in a rank
order: Lombardia>Veneto>Emilia Romagna>Lazio>Pie-
monte>Toscana, see Table 1). A large participation of
centers contacted for the interview was obtained. Of 158
hospices registered, 122 centers agreed to the interview
(77.2%). Six centers (3.8%) refused to participate and 30
(19%) were unattainable or non-existent despite the
publishing of their data in the website of Osservatorio
Italiano di Cure Palliative. The 122 hospices had a global
availability of 1,375 beds (17 day-hospital beds) with a
mean of 11.2 (±4.5) beds for each hospice unit (Table 2). In
Abruzzo and Valle D’ Aosta, no hospice was available.
Data regarding the drug of choice for BcP and routes of
administration are presented in Table 3 and 4, oral
morphine being the most common practice. Morphine was
also frequently used parenterally, subcutaneously or intra-
venously. In four hospices, OTFC was unavailable or
bought by patients; and in one hospice, prescription of
OTFC required a specific request to hospital administration
(likely due to the cost of the drug).
Preferences on the doses to be used for treating BcP are
reported in Table 5. Most physicians provided doses of
opioids proportional to the opioid basal regimen (between
20% and 16% of the daily dose, in most cases),
independently of the preferred opioid or the route of
administration (oral morphine, subcutaneous or intravenous
morphine, or OTFC). Of interest, the choice of dose
titration was equally used in patients who were prescribed
OTFC or parenteral morphine (intravenously or subcutane-
ously). Finally, the choice of breakthrough medication on
the basis of opioid basal regimen was equally distributed
Table 1 Distribution of hospices and centers available for the
interview (from north to south to islands)
No answer Participating centers Total
Lombardia 11 39 50
Veneto 6 12 18
Piemonte 5 6 11
Trentino alt 0 3 3
Friuli venez 0 3 3
Liguria 1 4 5
Emilia romag 2 16 18
Toscana 1 9 10
Umbria 0 2 2
Marche 1 4 5
Lazio 6 6 12
Molise 0 1 1
Campania 1 1 2
Puglia 0 5 5
Basilicata 0 3 3
Calabria 0 2 2
Sardegna 0 3 3
Sicilia 2 3 5
Total 36 122 158
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(37 physicians answered yes, 42 physicians answered not,
and others did not responded).
Discussion
In the cancer population, BcP is a transitory flare of pain
superimposed on an otherwise stable pain pattern in
patients treated with opioids [8]. Recognition and appro-
priate management of BcP has been found to enhance
quality of life [9]. Although the literature has adequately
addressed the biologic basis, epidemiology, and manage-
ment of breakthrough pain, gaps exist in recognizing and
treating BcP in daily practice, even in potentially special-
ized centers, like palliative care units.
In the last decade, there has been a growing interest in
palliative care in Italy and new resources from the Health
Care System have been allocated for palliative care. Active
centers involved in palliative care progressively increased
with a large distribution in Northern Italy and several
hospices are now available for cancer and non cancer
palliative care population [7]. In Italy, the use of opioids in
the management of cancer pain has been for years at the
lowest levels compared with other European countries [6],
and this represents a barrier to an adequate treatment of the
different types of cancer pain, including BcP. In a previous
Italian survey, while the prevalence of BcP was 72.5%, BcP
was treated in 59.2% of cases with extra doses of opioids,
in 19.5% with NSAIDs while 21.3% of patients had no
specific treatment for BcP [5]. To make a comparison with
a country with a consolidated tradition in the use of opioids,
like UK, 81 of 87 patients in a non-specialized oncological
setting had been prescribed a strong opioid as BcP
Hospices available for interview Mean number of available beds (±SD)
Lombardia 39 11.4 (3.6)
Veneto 12 10.2 (5.3)
Piemonte 6 10.2 (2.0)
Trentino alt 3 8.0 (3.5)
Friuli venez 3 14.0 (5.3)
Liguria 4 10.5 (1.0)
Emilia romag 16 12.3 (5.1)
Toscana 9 8.9 (2.8)
Umbria 2 9.5 (3.5)
Marche 4 8.8 (2.7)
Lazio 6 19.5 (7.5)
Molise 1 11.0 (0.0)
Campania 1 10.0 (0.0)
Puglia 5 10.4 (2.2)
Basilicata 3 8.7 (4.1)
Calabria 2 9.5 (2.1)
Sardegna 3 10.0 (7.0)
Sicilia 3 13.3 (1.1)
Total 122 11.2 (±4.5)
Table 2 Number of hospices
and mean of available beds for
each unit in the different regions
(from north to south islands)
Table 4 Routes of administrations of choice
Oral 54
Subcutaneous 23
Intravenous 14
Subcutaneoua/intravenous 6
Transmucosal 4
Intramuscular 1
Oral/intravenous 1
Oral/subcutaneous 1
Subcutaneous/intramuscular 1
Total answers 105/122
Some answers were incomplete
Table 3 Drugs of choice
Morphine 93
OTFC 15
Morphine/OTFC 5
Morphine/NSAIDs 2
OTFC/oxycodone 1
NSAIDs/pregabalin 1
Transdermal fentanyl 1
Total answers 118/122
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medication [10], although only a minority used the opioid
every time they experienced BcP because of individual
concerns.
In this survey, the response rate was high and the
majority of specialized palliative care centers provided
information about their attitudes on the treatment of BcP.
Interesting points emerged. For example, clear geographic
differences in availability of hospice beds regrettably reflect
an unequal provision and access to palliative care services
across the country, with South and islands having the
lowest availability of hospice beds in comparison with
Northern regions, confirming differences in economical
development of these areas [7]. This disparity also impeded
any statistical comparison regarding BcP among regions.
Secondly, although BcP was treated in almost all the
units, the treatment was sometime unexpected and revealed
a poor knowledge of existing guidelines. Currently, the
options for the management of BcP are relatively limited.
OTFC has been shown to be effective and well tolerated in
a number of clinical trials [11]. However, its use has been
limited by a number of practical problems, also including
issues around the cost of the product [4, 11]. Other than
obvious worse indications (such as transdermal fentanyl or
pregabalin), a clear prevalence in the use of oral morphine
was evidenced, despite pain usually resolves before the
drug starts to work. Thus, in many instances, the decision is
not based on the best knowledge, but on other reasons, as
physicians’ preferences, availability, and probably costs.
Alternately, as patients are usually admitted to these
hospices when they have a limited survival [12], they do
not use OTFC because it requires active participation
difficult to obtain in severely ill patients.
Finally, the modality of using BcP medications was
explored. Controversies exist about the need for dose
titration, suggested in controlled studies of OTFC [13],
and the traditional method of using doses of oral morphine
proportional to the daily opioid regimen [4, 14, 15]. Most
physicians preferred to provide doses of opioids propor-
tional to the basal opioid regimen, either with morphine,
subcutaneously or intravenously, and OTFC. Similarly, the
low number of physicians who preferred to titrate patients
did so either with morphine and OTFC.
Considering the low number of respondents who were
prescribed OTFC, the figures seem to confirm a tendency to
use different approaches also on the basis of economical
restrictions, morphine remaining the cheapest treatment for
BcP. It was confirmed by the unavailability or restrictions of
OTFC in some centers. Of interest, a consistent number of
hospice physicians used parenteral morphine, which should
better fit timing for BcP in comparison with oral morphine
which has an inappropriate delayed analgesic effect.
As this is the first national survey on the use of BcP
medication, comparison with experiences of other countries
is unlikely due to unavailability of data. Setting and stage
of disease may influence epidemiology and treatment of
BcP. Differently from the hospice setting, where prescrip-
tions are more likely to be given and the choice is based on
physicians’ decision and resources, the only existing study
performed in UK in still active oncologic outpatients
showed that patients were determinant in decision making.
Despite that almost all patients were prescribed a BcP
medication, they did not take BcP medication due to lack of
intensity of pain or concerns about BcP medication [10]. It
has been shown in a previous study performed in home-
care patients with a limited survival that the incidence of
BcP, particularly movement-related pain, may decrease with
the worsening of disease, as a consequence of a reduced
level of activity or because patients stop even minimal
activity after feeling an increase in pain intensity [16].
As recognition and treatment of BcP depend on the
education and knowledge of palliative care physicians, it is
important to systematically explore the attitudes of palliative
care physicians in hospices or palliative care units existing in
Italy. The answers’ rate was high, so that the sample could be
quite representative of how BcP is treated in a country where
there has been a traditional limitation in the education and use
of opioids in cancer pain and economical considerations may
prevail. These findings suggest the need for improved
education on behalf of physicians on the assessment and
treatment of BcP, particularly in a potentially specialized
setting, such as palliative care units. Data provided by this
survey suggest the need of implementation of the knowledge
on cancer pain and BcP management in all the existing
palliative care programs, considering the poor availability of
this information provided by schools of medicine. This topic in
fact is a neglected topic during the traditional courses in the
university. No specialization exists in Italy and few postgrad-
uate courses are available. This data reflects a national modality
of approach for the management of BcP. No information exists
from other countries. Similar data gathered in other countries
should be helpful in the recognition of an important problem as
BcP, and could suggest how to resolve them in a European
perspective. The choice of BcPmedications should be based on
the best cost-efficacy ratio rather than solely on economical
considerations. A range of new products with potential further
Titration 26
1:6 29
1:5 36
1:4 6
1.3 4
1:2 1
Total answers 02/122
Table 5 Frequency of titration
dosing or doses proportional to
background opioid dosing for
breakthrough pain medication
Some answers were incomplete
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advantages on available preparations will be available in the
next future. These new preparations will be successful if health
care professionals prescribe them appropriately and patients
take them accordingly.
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